Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to:

Match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent (DES);
Come in a range of sizes and lengths
Provide equivalent mechanical performance (radial strength) to the best-in-classDrug Eluting Stent (DES) products
Generate fewer clinical adverse events than current Drug Eluting Stent (DES)
Be resorbed within 24 months leaving nothing behind which might complicate future revascularisations
Overcome the high in-stent late lumen loss (narrowing of the vessel once the stent has dissolved) which has limited the adoption of first generation products

Accomplishing the above will support the positioning of a premium priced BRS product which could claim significant stent market share with higher margins than existing Bare Metal Stent (BMS) and Drug Eluting Stent (DES);

Contact supplier

Stay in the loop!